Albemarle Reports Net Sales Increase of 10% for Third Quarter 2023
- None.
- None.
Third-Quarter 2023 and Recent Highlights
(Unless otherwise stated, all percentage changes represent year-over-year comparisons)
- Net sales of
, an increase of$2.3 billion 10% - Net income of
, or$302.5 million per diluted share$2.57 - Adjusted diluted EPS of
$2.74 - Adjusted EBITDA of
$453.3 million - Signed agreements with Caterpillar Inc. to collaborate on solutions to support the full circular battery value chain and sustainable mining operations
- Received
critical materials award from the$90 million U.S. Department of Defense to support restart ofKings Mountain, NC mine - Completed the previously disclosed transaction to amend and simplify the MARBL joint venture with Mineral Resources Limited
- On track to achieve more than
in productivity benefits in 2023$170 million - 2023 net sales are now expected to increase approximately
30% to35% year-over-year and 2023 adjusted EBITDA is expected to be flat to slightly down year-over-year
"Albemarle grew net sales by
2023 Corporate Outlook
The company's full-year 2023 outlook reflects expected financial performance assuming recent lithium market pricing continues for the remainder of the year, as consistent with our standard practice. Net sales are expected to increase
FY 2023 Outlook as of August 2, 2023 | FY 2023 Outlook as of November 1, 2023 | ||
Net sales | |||
Adjusted EBITDA(a) | |||
Adjusted EBITDA Margin(a) | |||
Adjusted Diluted EPS(a) | |||
Net Cash from Operations | |||
Capital Expenditures |
(a) | The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. See "Additional Information regarding Non-GAAP Measures" for more information. |
Third Quarter 2023 Results
In millions, except per share amounts | Q3 2023 | Q3 2022 | $ Change | % Change | |||
Net sales | $ 2,310.6 | $ 2,091.8 | $ 218.8 | 10.5 % | |||
Net income attributable to Albemarle Corporation | $ 302.5 | $ 897.2 | $ (594.7) | (66.3) % | |||
Adjusted EBITDA(a) | $ 453.3 | $ 1,190.0 | $ (736.7) | (61.9) % | |||
Diluted earnings per share | $ 2.57 | $ 7.61 | $ (5.04) | (66.2) % | |||
Non-operating pension and OPEB items(a) | — | (0.03) | |||||
Non-recurring and other unusual items(a) | 0.17 | (0.08) | |||||
Adjusted diluted earnings per share(a)(b) | $ 2.74 | $ 7.50 | $ (4.76) | (63.5) % |
(a) | See Non-GAAP Reconciliations for further details. |
(b) | Totals may not add due to rounding. |
Net sales for the third quarter of 2023 were
The effective income tax rate for the third quarter of 2023 was
Business Segment Results
Beginning January 1, 2023, the company re-segmented its operating business units. The results from 2022 are recast to align with the new structure.
Energy Storage Results
In millions | Q3 2023 | Q3 2022 | $ Change | % Change | |||
Net Sales | $ 1,697.2 | $ 1,414.1 | $ 283.1 | 20.0 % | |||
Adjusted EBITDA | $ 407.5 | $ 1,084.6 | $ (677.2) | (62.4) % |
Energy Storage net sales for the third quarter of 2023 were
2023 Energy Storage Outlook
Energy Storage net sales for the full year are estimated to range between
In October, Albemarle finalized simplified commercial arrangements related to its MARBL joint venture. Under the revised agreements, Albemarle will take full ownership of the Kemerton lithium processing facility and
Albemarle continues to expand its global portfolio of lithium conversion capacity and world-class resource portfolio with several notable developments in the third quarter. In August, the company completed a
Specialties Results
In millions | Q3 2023 | Q3 2022 | $ Change | % Change | |||
Net Sales | $ 352.7 | $ 441.9 | $ (89.2) | (20.2) % | |||
Adjusted EBITDA | $ 46.3 | $ 133.6 | $ (87.3) | (65.3) % |
Specialties net sales for the third quarter of 2023 were
2023 Specialties Outlook
Albemarle is updating its 2023 outlook for Specialties net sales to approximately
Ketjen Results
In millions | Q3 2023 | Q3 2022 | $ Change | % Change | |||
Net Sales | $ 260.7 | $ 235.8 | $ 24.9 | 10.6 % | |||
Adjusted EBITDA | $ 15.2 | $ 4.6 | $ 10.5 | 227.1 % |
Ketjen net sales of
2023 Ketjen Outlook
Albemarle expects Ketjen net sales of approximately
Cash Flow and Capital Deployment
Cash from operations of
Albemarle's primary capital allocation priorities are to invest in organic and inorganic opportunities to drive profitable growth, maintain its financial flexibility and investment grade credit rating, and fund its dividends.
Balance Sheet and Liquidity
As of September 30, 2023, Albemarle had estimated liquidity of approximately
Earnings Call
Date: | Thursday, November 2, 2023 |
Time: | 9:00 AM Eastern time |
Dial-in ( | 1.888.330.2007 |
Dial-in (International): | 1.646.960.0105 |
Passcode: | 5205664 |
The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com.
About Albemarle
Albemarle Corporation (NYSE: ALB) leads the world in transforming essential resources into critical ingredients for mobility, energy, connectivity, and health. We partner to pioneer new ways to move, power, connect and protect with people and planet in mind. A reliable and high-quality global supply of lithium and bromine allow us to deliver advanced solutions for our customers. Learn more about how the people of Albemarle are enabling a more resilient world at albemarle.com and on Twitter @AlbemarleCorp.
Albemarle regularly posts information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, Securities and Exchange Commission ("SEC") filings and other information regarding the company, its businesses and the markets it serves.
Forward-Looking Statements
This press release contains statements concerning our expectations, anticipations and beliefs regarding the future, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as "anticipate," "believe," "estimate," "expect," "guidance," "intend," "may," "outlook," "should," "would," and "will". Forward-looking statements may include statements regarding expected: financial and operating results, production capacity, volumes, and prices, demand for Albemarle's products, capital projects, acquisition and divestiture transactions, market and economic trends, and all other information relating to matters that are not historical facts. Factors that could cause Albemarle's actual results to differ materially from the outlook expressed or implied in any forward-looking statement include: changes in economic and business conditions; financial and operating performance of customers; timing and magnitude of customer orders; fluctuations in lithium market prices; production volume shortfalls; increased competition; changes in product demand; availability and cost of raw materials and energy; technological change and development; fluctuations in foreign currencies; changes in laws and government regulation; regulatory actions, proceedings, claims or litigation; cyber-security breaches, terrorist attacks, industrial accidents or natural disasters; political unrest and war, including the situation in the
Albemarle Corporation and Subsidiaries Consolidated Statements of Income (In Thousands Except Per Share Amounts) (Unaudited) | |||||||
Three Months Ended | Nine Months Ended | ||||||
September 30, | September 30, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Net sales | |||||||
Cost of goods sold | 2,255,662 | 1,047,991 | 5,371,077 | 2,625,858 | |||
Gross profit | 54,934 | 1,043,814 | 1,889,961 | 2,073,268 | |||
Selling, general and administrative expenses | 173,866 | 134,479 | 725,242 | 375,989 | |||
Research and development expenses | 21,082 | 18,358 | 62,972 | 51,827 | |||
Loss on sale of interest in properties | — | — | — | 8,400 | |||
Operating (loss) profit | (140,014) | 890,977 | 1,101,747 | 1,637,052 | |||
Interest and financing expenses | (29,332) | (29,691) | (81,686) | (98,934) | |||
Other income, net | 11,182 | 7,974 | 147,628 | 32,237 | |||
(Loss) income before income taxes and equity in net | (158,164) | 869,260 | 1,167,689 | 1,570,355 | |||
Income tax expense | (8,551) | 196,938 | 311,399 | 366,486 | |||
(Loss) income before equity in net income of | (149,613) | 672,322 | 856,290 | 1,203,869 | |||
Equity in net income of unconsolidated investments (net | 470,306 | 258,884 | 1,417,545 | 449,476 | |||
Net income | 320,693 | 931,206 | 2,273,835 | 1,653,345 | |||
Net income attributable to noncontrolling interests | (18,160) | (33,991) | (82,679) | (95,974) | |||
Net income attributable to Albemarle Corporation | $ 302,533 | $ 897,215 | |||||
Basic earnings per share | $ 2.58 | $ 7.66 | $ 18.68 | $ 13.30 | |||
Diluted earnings per share | $ 2.57 | $ 7.61 | $ 18.60 | $ 13.23 | |||
Weighted-average common shares outstanding – basic | 117,349 | 117,136 | 117,304 | 117,106 | |||
Weighted-average common shares outstanding – diluted | 117,783 | 117,869 | 117,797 | 117,749 |
Albemarle Corporation and Subsidiaries Condensed Consolidated Balance Sheets (In Thousands) (Unaudited) | |||
September 30, | December 31, | ||
2023 | 2022 | ||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ 1,601,668 | $ 1,499,142 | |
Trade accounts receivable | 1,179,012 | 1,190,970 | |
Other accounts receivable | 528,744 | 185,819 | |
Inventories | 3,404,212 | 2,076,031 | |
Other current assets | 411,926 | 234,955 | |
Total current assets | 7,125,562 | 5,186,917 | |
Property, plant and equipment | 10,929,150 | 9,354,330 | |
Less accumulated depreciation and amortization | 2,620,535 | 2,391,333 | |
Net property, plant and equipment | 8,308,615 | 6,962,997 | |
Investments | 1,254,041 | 1,150,553 | |
Other assets | 328,518 | 250,558 | |
Goodwill | 1,606,077 | 1,617,627 | |
Other intangibles, net of amortization | 260,541 | 287,870 | |
Total assets | $ 18,883,354 | $ 15,456,522 | |
LIABILITIES AND EQUITY | |||
Current liabilities: | |||
Accounts payable to third parties | $ 1,812,168 | $ 1,533,624 | |
Accounts payable to related parties | 795,088 | 518,377 | |
Accrued expenses | 689,106 | 505,894 | |
Current portion of long-term debt | 162,351 | 2,128 | |
Dividends payable | 46,661 | 46,116 | |
Income taxes payable | 436,238 | 134,876 | |
Total current liabilities | 3,941,612 | 2,741,015 | |
Long-term debt | 3,495,971 | 3,214,972 | |
Postretirement benefits | 32,797 | 32,751 | |
Pension benefits | 153,955 | 159,571 | |
Other noncurrent liabilities | 807,051 | 636,596 | |
Deferred income taxes | 289,529 | 480,770 | |
Commitments and contingencies | |||
Equity: | |||
Albemarle Corporation shareholders' equity: | |||
Common stock | 1,174 | 1,172 | |
Additional paid-in capital | 2,945,975 | 2,940,840 | |
Accumulated other comprehensive loss | (700,972) | (560,662) | |
Retained earnings | 7,651,638 | 5,601,277 | |
Total Albemarle Corporation shareholders' equity | 9,897,815 | 7,982,627 | |
Noncontrolling interests | 264,624 | 208,220 | |
Total equity | 10,162,439 | 8,190,847 | |
Total liabilities and equity | $ 18,883,354 | $ 15,456,522 |
Albemarle Corporation and Subsidiaries Selected Consolidated Cash Flow Data (In Thousands) (Unaudited) | |||
Nine Months Ended September 30, | |||
2023 | 2022 | ||
Cash and cash equivalents at beginning of year | $ 1,499,142 | $ 439,272 | |
Cash flows from operating activities: | |||
Net income | 2,273,835 | 1,653,345 | |
Adjustments to reconcile net income to cash flows from operating activities: | |||
Depreciation and amortization | 285,801 | 215,280 | |
Loss on sale of interest in properties | — | 8,400 | |
Stock-based compensation and other | 29,465 | 24,649 | |
Equity in net income of unconsolidated investments (net of tax) | (1,417,545) | (449,476) | |
Dividends received from unconsolidated investments and nonmarketable securities | 1,939,225 | 350,895 | |
Pension and postretirement benefit | 5,925 | (12,299) | |
Pension and postretirement contributions | (12,243) | (10,929) | |
Unrealized (gain) loss on investments in marketable securities | (36,740) | 3,864 | |
Loss on early extinguishment of debt | — | 19,219 | |
Deferred income taxes | (182,764) | 77,968 | |
Working capital changes | (1,332,042) | (1,004,236) | |
Non-cash transfer of | 17,132 | 115,969 | |
Other, net | (146,509) | (37,047) | |
Net cash provided by operating activities | 1,423,540 | 955,602 | |
Cash flows from investing activities: | |||
Acquisitions, net of cash acquired | (43,207) | — | |
Capital expenditures | (1,465,193) | (815,934) | |
(Purchases) sales of marketable securities, net | (205,952) | 3,132 | |
Investments in equity investments and nonmarketable securities | (1,279) | (507) | |
Net cash used in investing activities | (1,715,631) | (813,309) | |
Cash flows from financing activities: | |||
Repayments of long-term debt and credit agreements | — | (455,000) | |
Proceeds from borrowings of long-term debt and credit agreements | 300,000 | 1,964,216 | |
Other debt repayments, net | 172,791 | (391,067) | |
Fees related to early extinguishment of debt | — | (9,767) | |
Dividends paid to shareholders | (140,251) | (138,165) | |
Dividends paid to noncontrolling interests | (79,393) | (44,208) | |
Proceeds from exercise of stock options | 117 | 1,590 | |
Withholding taxes paid on stock-based compensation award distributions | (26,166) | (12,150) | |
Other | (191) | (4,198) | |
Net cash provided by financing activities | 226,907 | 911,251 | |
Net effect of foreign exchange on cash and cash equivalents | 167,710 | (110,013) | |
Increase in cash and cash equivalents | 102,526 | 943,531 | |
Cash and cash equivalents at end of period | $ 1,601,668 | $ 1,382,803 |
Albemarle Corporation and Subsidiaries Consolidated Summary of Segment Results (In Thousands) (Unaudited) | |||||||
Three Months Ended | Nine Months Ended | ||||||
September 30, | September 30, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Net sales: | |||||||
Energy Storage | |||||||
Specialties | 352,722 | 441,928 | 1,142,802 | 1,354,950 | |||
Ketjen | 260,711 | 235,824 | 714,326 | 664,026 | |||
Total net sales | |||||||
Adjusted EBITDA: | |||||||
Energy Storage | $ 407,476 | ||||||
Specialties | 46,307 | 133,558 | 268,665 | 433,534 | |||
Ketjen | 15,159 | 4,635 | 72,584 | 31,337 | |||
Total segment adjusted EBITDA | 468,942 | 1,222,836 | 3,086,929 | 2,318,278 | |||
Corporate | (15,655) | (32,870) | (5,657) | (86,173) | |||
Total adjusted EBITDA | $ 453,287 |
See accompanying non-GAAP reconciliations below.
Additional Information regarding Non-GAAP Measures
It should be noted that adjusted net income attributable to Albemarle Corporation, adjusted diluted earnings per share, non-operating pension and other post-employment benefit ("OPEB") items per diluted share, non-recurring and other unusual items per diluted share, adjusted effective income tax rates, EBITDA, adjusted EBITDA (on a consolidated basis), EBITDA margin and adjusted EBITDA margin are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in
A description of other non-GAAP financial measures that Albemarle uses to evaluate its operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also is available on Albemarle's website at https://investors.albemarle.com. The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the company's results calculated in accordance with GAAP.
ALBEMARLE CORPORATION AND SUBSIDIARIES
Non-GAAP Reconciliations
(Unaudited)
See below for a reconciliation of adjusted net income attributable to Albemarle Corporation, EBITDA and adjusted EBITDA (on a consolidated basis), which are non-GAAP financial measures, to Net income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reported in accordance with GAAP. Reconciliation of adjusted EBITDA on a segment basis is also provided. Adjusted net income attributable to Albemarle Corporation is defined as net income before the non-recurring, other unusual and non-operating pension and other post-employment benefit (OPEB) items as listed below. The non-recurring and unusual items may include acquisition and integration related costs, gains or losses on sales of businesses, restructuring charges, facility divestiture charges, certain litigation and arbitration costs and charges, and other significant non-recurring items. EBITDA is defined as net income attributable to Albemarle Corporation before interest and financing expenses, income tax expense, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA plus or minus the non-recurring, other unusual and non-operating pension and OPEB items as listed below.
Three Months Ended | Nine Months Ended | ||||||||||||||
September 30, | September 30, | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
In thousands, except percentages and per | $ | % of | $ | % of | $ | % of | $ | % of | |||||||
Net income attributable to Albemarle | $ 2,191,156 | $ 1,557,371 | |||||||||||||
Add back: | |||||||||||||||
Non-operating pension and OPEB items | 386 | (3,936) | 1,141 | (12,021) | |||||||||||
Non-recurring and other unusual items | 19,674 | (9,789) | 210,094 | 24,023 | |||||||||||
Adjusted net income attributable to | $ 2,402,391 | $ 1,569,373 | |||||||||||||
Adjusted diluted earnings per share | $ 2.74 | $ 7.50 | $ 20.39 | $ 13.33 | |||||||||||
Weighted-average common shares | 117,783 | 117,869 | 117,797 | 117,749 | |||||||||||
Net income attributable to Albemarle | 13.1 % | 42.9 % | $ 2,191,156 | 30.2 % | $ 1,557,371 | 33.1 % | |||||||||
Add back: | |||||||||||||||
Interest and financing expenses | 29,332 | 1.3 % | 29,691 | 1.4 % | 81,686 | 1.1 % | 98,934 | 2.1 % | |||||||
Income tax expense | (8,551) | (0.4) % | 196,938 | 9.4 % | 311,399 | 4.3 % | 366,486 | 7.8 % | |||||||
Depreciation and amortization | 105,445 | 4.6 % | 77,713 | 3.7 % | 285,801 | 3.9 % | 215,280 | 4.6 % | |||||||
EBITDA | 428,759 | 18.6 % | 1,201,557 | 57.4 % | 2,870,042 | 39.5 % | 2,238,071 | 47.6 % | |||||||
Non-operating pension and OPEB items | 620 | — % | (5,027) | (0.2) % | 1,833 | — % | (15,345) | (0.3) % | |||||||
Non-recurring and other unusual items | 23,908 | 1.0 % | (6,564) | (0.3) % | 209,397 | 2.9 % | 9,379 | 0.2 % | |||||||
Adjusted EBITDA | 19.6 % | $ 1,189,966 | 56.9 % | $ 3,081,272 | 42.4 % | $ 2,232,105 | 47.5 % | ||||||||
Net sales | $ 2,310,596 | $ 2,091,805 | $ 7,261,038 | $ 4,699,126 |
Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to Albemarle's operating segments and are included in the Corporate category. In addition, the company believes that these components of pension cost are mainly driven by market performance, and the company manages these separately from the operational performance of the company's businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other income (expenses), net. Non-operating pension and OPEB items were as follows (in thousands):
Three Months Ended | Nine Months Ended | ||||||
September 30, | September 30, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Interest cost | $ 9,054 | $ 5,857 | $ 27,091 | $ 17,683 | |||
Expected return on assets | (8,434) | (10,884) | (25,258) | (33,028) | |||
Total | $ 620 | $ (5,027) | $ 1,833 | $ (15,345) |
In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):
Three Months Ended | Nine Months Ended | ||||||
September 30, | September 30, | ||||||
2023 | 2022 | 2023 | 2022 | ||||
Acquisition and integration related costs(1) | $ 0.07 | $ 0.01 | $ 0.14 | $ 0.06 | |||
Loss on sale of interest in properties(2) | — | — | — | 0.07 | |||
Loss on early extinguishment of debt(3) | — | — | — | 0.13 | |||
Mark-to-market loss (gain) on public equity securities(4) | 0.17 | (0.07) | (0.21) | (0.07) | |||
Legal accrual(5) | — | — | 1.82 | — | |||
Other(6) | (0.08) | 0.01 | 0.03 | — | |||
Tax related items(7) | 0.01 | (0.03) | — | 0.01 | |||
Total non-recurring and other unusual items | $ 0.17 | $ (0.08) | $ 1.78 | $ 0.20 |
(1) | Costs related to the acquisition, integration and divestitures for various significant projects, recorded in Selling, general and administrative expenses for the three and nine months ended September 30, 2023 were |
(2) | Included in Loss on sale of interest in properties for the nine months ended September 30, 2022 is an expense of |
(3) | Included in Interest and financing expenses for the nine months ended September 30, 2022 is a loss on early extinguishment of debt of |
(4) | Loss (gain) of |
(5) | Accrual of |
(6) | Other adjustments for the three months ended September 30, 2023 included amounts recorded in: |
| |
After income taxes, these net gains totaled | |
Other adjustments for the nine months ended September 30, 2023 included amounts recorded in: | |
| |
After income taxes, these net charges totaled | |
Other adjustments for the three months ended September 30, 2022 included amounts recorded in: | |
| |
After income taxes, these net charges totaled | |
Other adjustments for the nine months ended September 30, 2022 included amounts recorded in: | |
| |
After income taxes, these net charges totaled | |
(7) | Included in Income tax expense for the three and nine months ended September 30, 2023 are discrete net tax expense of |
Included in Income tax expense for the three and nine months ended September 30, 2022 are discrete net tax benefits of |
See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reported in accordance with GAAP (in thousands, except percentages).
Income before | Income tax expense | Effective income tax rate | |||
Three months ended September 30, 2023 | |||||
As reported | $ (158,164) | $ (8,551) | 5.4 % | ||
Non-recurring, other unusual and non-operating pension and OPEB | 24,528 | 4,468 | |||
As adjusted | $ (133,636) | $ (4,083) | 3.1 % | ||
Three months ended September 30, 2022 | |||||
As reported | $ 869,260 | $ 196,938 | 22.7 % | ||
Non-recurring, other unusual and non-operating pension and OPEB | (11,592) | 2,133 | |||
As adjusted | $ 857,668 | $ 199,071 | 23.2 % | ||
Nine months ended September 30, 2023 | |||||
As reported | $ 1,167,689 | $ 311,399 | 26.7 % | ||
Non-recurring, other unusual and non-operating pension and OPEB | 211,230 | (5) | |||
As adjusted | $ 1,378,919 | $ 311,394 | 22.6 % | ||
Nine months ended September 30, 2022 | |||||
As reported | $ 1,570,355 | $ 366,486 | 23.3 % | ||
Non-recurring, other unusual and non-operating pension and OPEB | 13,252 | 1,250 | |||
As adjusted | $ 1,583,607 | $ 367,736 | 23.2 % |
View original content to download multimedia:https://www.prnewswire.com/news-releases/albemarle-reports-net-sales-increase-of-10-for-third-quarter-2023-301974804.html
SOURCE Albemarle Corporation
FAQ
What were Albemarle Corporation's Q3 2023 net sales?
What was Albemarle Corporation's net income in Q3 2023?
What agreements did Albemarle Corporation sign in Q3 2023?
What award did Albemarle Corporation receive from the U.S. Department of Defense?